

**c.) Amendments to the Claims**

Please cancel claims 59 and 64-67 without prejudice or disclaimer of the subject matter thereof.

Please amend claims 58, 60, 62 and 63 as follows:

1. (withdrawn) A method of modulating cell growth in a mammal said method comprising administering to said mammal an effective amount of an agent for time and under conditions sufficient to modulate the expression of a genetic sequence encoding inhibin.
2. (withdrawn) A method according to claim 1 wherein said cells are prostate cells.
3. (withdrawn) A method according to claim 2 wherein said prostate cells are malignant.
4. (withdrawn) A method according to claim 1 or 2 or 3 wherein said inhibin is  $\alpha$ -inhibin.
5. (withdrawn) A method according to claim 4 wherein said modulation of the expression of said genetic sequence is up-regulation.
6. (withdrawn) A method according to claim 5 wherein said up-regulation inhibits cell growth.
7. (withdrawn) A method of modulating cell growth in a mammal said method comprising administering to said mammal an effective amount of inhibin.
8. (withdrawn) A method according to claim 7 wherein said cells are prostate cells.
9. (withdrawn) A method according to claim 8 wherein said prostate cells are malignant.
10. (withdrawn) A method according to claim 7 or 8 or 9 wherein said inhibin is  $\alpha$ -inhibin.
11. (withdrawn) A method according to claim 10 wherein said modulation of cell growth is inhibition of cell growth.
12. (withdrawn) A method of modulating cell growth in a mammal said method comprising administering to said mammal an effective amount of an inhibin antagonist.
13. (withdrawn) A method according to claim 12 wherein said cells are prostate cells.
14. (withdrawn) A method of treating a mammal said method comprising administering to said mammal an effective amount of an agent for a time and under conditions sufficient to modulate the expression of a genetic sequence encoding inhibin.
15. (withdrawn) A method according to claim 14 wherein said cells are prostate cells.
16. (withdrawn) A method according to claim 15 wherein said prostate cells are malignant.

17. (withdrawn) A method according to claim 14 or 15 or 16 wherein said inhibin is  $\alpha$ -inhibin.
18. (withdrawn) A method according to claim 17 wherein said modulation of the expression of said genetic sequence is up-regulation.
19. (withdrawn) A method according to claim 18 where said up-regulation inhibits cell growth
20. (withdrawn) A method of treating a mammal said method comprising administering to said mammal an effective amount of inhibin.
21. (withdrawn) A method according to claim 20 wherein said cells are prostate cells.
22. (withdrawn) A method according to claim 21 wherein said prostate cells are malignant.
23. (withdrawn) A method according to claim 20 or 21 or 22 wherein said inhibin is  $\alpha$ -inhibin.
24. (withdrawn) A method according to claim 23 wherein said modulation of cell growth is inhibition of cell growth.
25. (withdrawn) A method of treating a mammal said method comprising administering to said mammal an effective amount of an inhibin antagonist.
26. (withdrawn) A method according to claim 25 wherein said cells are prostate cells.
27. - 39. (previously canceled).
40. (withdrawn) An agent for use in modulating the expression of a genetic sequence encoding inhibin wherein modulating expression of said genetic sequence modulates cell growth.
41. (withdrawn) An agent according to claim 40 wherein said cells are prostate cells.
42. (withdrawn) An agent according to claim 41 wherein said prostate cells are malignant.
43. (withdrawn) An agent according to claim 40 or 41 or 42 wherein said inhibin is  $\alpha$ -inhibin.
44. (withdrawn) An agent according to claim 43 wherein said modulation of the expression of said genetic sequence is up-regulation.
45. (withdrawn) An agent according to claim 44 wherein said up-regulation inhibits cell growth.
46. (withdrawn) An agent for use in the modulation of cell growth in a mammal comprising inhibin.
47. (withdrawn) An agent according to claim 46 wherein said cells are prostate cells.

48. (withdrawn) An agent according to claim 47 wherein said prostate cells are malignant.
49. (withdrawn) An agent according to claim 46 or 47 or 48 wherein said inhibin is  $\alpha$ -inhibin.
50. (withdrawn) An agent according to claim 49 wherein said up-regulation inhibits cell growth.
51. (withdrawn) An agent for use in the modulation of cell growth in a mammal comprising an inhibin antagonist.
52. (withdrawn) An agent according to claim 51 wherein said cells are prostate cells.
53. (withdrawn) A pharmaceutical composition comprising an agent capable of modulating expression of a genetic sequence encoding inhibin thereby modulating cell growth and one or more pharmaceutically acceptable carriers and/or diluents.
54. (withdrawn) A claim according to claim 53 wherein said inhibin is  $\alpha$ -inhibin.
55. (withdrawn) A pharmaceutical composition comprising inhibin capable of modulating cell growth and one or more pharmaceutically acceptable carriers and/or diluents.
56. (withdrawn) A pharmaceutical composition according to claim 55 wherein said inhibin is  $\alpha$ -inhibin.
57. (withdrawn) A pharmaceutical composition comprising an inhibin antagonist capable of modulating cell growth and one or more pharmaceutically acceptable carriers and/or diluents.
58. (currently amended) A method of screening for a mammal having prostate cancer or predisposition to prostate cancer, said method comprising screening for modifications to inhibin protein levels in said mammal wherein modification of said inhibin protein levels relative to the inhibin protein levels in a normal mammal is indicative of said mammal being predisposed to develop prostate cancer or having already developed prostate cancer.
59. (currently canceled).
60. (previously amended) The method according to claim 58 wherein said inhibin is  $\alpha$ -inhibin.
61. (withdrawn) The method according to claim 60 wherein said  $\alpha$ -inhibin is  $\alpha$ N or isoform thereof.
62. (previously amended) The method according to claim 60 wherein said  $\alpha$ -inhibin is  $\alpha$ C or isoform thereof.

63. (currently amended) The method according to claim 58 or 60 or 61 or 62 wherein said modification is absent down-regulation of inhibin levels.

64. – 67. (currently canceled).

Please add the following as new claim 68:

68. (new) The method according to claim 63 wherein said down-regulation is the absence of inhibin expression.